FISH probe market seen reaching $2.39 billion by 2030

The fluorescent in situ hybridization probe market is projected to grow from $1.68 billion in 2025 to $1.8 billion in 2026, with long-term demand tied to personalized medicine, genetic testing and molecular diagnostics. The Business Research Company says the market could reach $2.39 billion by 2030 as multiplex probes, AI image analysis and broader clinical adoption expand use cases.

Why it matters: - Fluorescent in situ hybridization probes are a core tool for genetic analysis in personalized medicine, cancer research and rare-disease diagnostics. - Faster growth in personalized healthcare is increasing demand for precise chromosomal-level testing. - The market's expansion signals more adoption of molecular diagnostics across clinical, research and biotech settings.

What happened: - The Business Research Company published a 2026 market report on the fluorescent in situ hybridization probe market. - The report says the market rose from $1.68 billion in 2025 to $1.8 billion in 2026. - The report forecasts the market will reach $2.39 billion by 2030. - The report was released Aug. 7, 2026. - A free sample of the report is available. - The full market report is also available.

The details: - The market's recent 7.1% CAGR reflects demand supported by limited supply of fluorescent probes, reliance on traditional single-color FISH techniques, greater awareness of genetic diagnostics, higher funding for molecular biology research and wider use of fluorescence microscopy. - The forecast period points to a 7.3% CAGR through 2030. - Growth drivers include multiplex and combinatorial barcoded probes, expanded use in personalized healthcare, more pharmaceutical and biotechnology research, tighter regulatory oversight and standardization, and AI-powered image analysis and data analytics. - Emerging trends include broader clinical adoption, more multiplex and high-throughput screening, increased use in genetic and agricultural studies, better imaging technologies and tailored probe development for individualized medicine. - A fluorescent in situ hybridization probe is a short single-stranded DNA or RNA sequence tagged with a fluorescent dye. - The probe binds to a complementary DNA or RNA segment inside a cell or tissue sample. - The technique lets scientists and clinicians visualize genetic material within chromosomes, nuclei or tissue slices under a fluorescence microscope. - Personalized medicine is one of the main growth drivers because FISH probes help detect chromosomal genetic variations that can inform treatment decisions. - Demand for customized healthcare is rising as patients and providers seek more specific diagnostic insight. - The Personalized Medicine Coalition said in February 2024 that the FDA approved 16 new personalized therapies for rare diseases in 2023, up from six in 2022.

Between the lines: - The report positions FISH probes as a bridge between basic molecular research and more targeted clinical care. - The strongest growth case is not from one single application, but from several overlapping shifts: multiplex testing, AI-assisted analysis and broader clinical use. - North America's current lead suggests the market still depends heavily on advanced healthcare infrastructure and research spending. - Asia-Pacific's faster growth outlook points to rising diagnostic capacity and biotech investment outside the U.S. and Europe.

What's next: - The report expects continued market gains through 2030 as personalized medicine expands. - The company says future market intelligence will include market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards, hotspot infographics and updated graphics and tables. - Regional expansion in Asia-Pacific is expected to be a key growth story over the forecast period.

The bottom line: - FISH probe demand is moving from a specialized research market toward broader clinical use, with personalized medicine and AI-enabled diagnostics doing most of the work.